When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Dhruv Bhutani has been writing about consumer technology since 2008, offering deep insights into the Android smartphone landscape through features and opinion pieces. He joined Android Police in 2023, ...

Have you ever opened your Apple Notes app, only to feel overwhelmed by a chaotic sea of random thoughts, to-do lists, and half-finished ideas? If so, you’re not alone. Many users rely on outdated ...

Background: Generative artificial intelligence (AI) tools are increasingly being used as “ambient scribes” to generate drafts for clinical notes from patient encounters. Despite rapid adoption, few ...

Perhaps the biggest change for Notes this year is the brand new design with Liquid Glass. Though the basic structure of the app remains the same, everything looks and feels more modern thanks to ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...

Anu is a Features author at Android Police. You'll find her writing in-depth pieces about automation tools, productivity apps, and explainers. Before joining AP, she used to write for prominent tech ...